Search Results for "darbepoetin alfa"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for darbepoetin alfa. Results 1 to 2 of 2 total matches.
See also: Aranesp
Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
INNO2VATE-1 (n=369)
Vadadustat 1.26 g/dL* 1.42 g/dL*
Darbepoetin alfa 1.58 g/dL 1.50 g/dL
INNO2VATE-2 (n ...
The FDA has approved the hypoxia-inducible factor
prolyl hydroxylase inhibitor (HIF-PHI) vadadustat
(Vafseo – Akebia) for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 3 months. Vadadustat is
the second HIF-PHI to be approved in the US for this
indication; daprodustat (Jesduvroq) was approved
earlier, but it was withdrawn from the US market in
2024 for commercial reasons.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):27-9 doi:10.58347/tml.2025.1722b | Show Introduction Hide Introduction
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
not on dialysis
(ASCEND-ND), daprodustat was noninferior to
darbepoetin alfa in raising hemoglobin levels ...
The FDA has approved daprodustat (Jesduvroq –
GSK), a hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 4 months. It is the first
HIF-PHI and the first oral drug to be approved in the
US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 doi:10.58347/tml.2024.1696a | Show Introduction Hide Introduction